RNXT - Margin dodolan resik RenovoRx, Inc.

RenovoRx Inc - logo grafis emiten RNXT

RenovoRx, Inc. (RNXT) is developing the RenovoCath platform for local chemotherapy, supported by FDA orphan drug status. The realization margin ratio helps track financial stability, with the value holding at -469.00. The company attracts bioengineers through its innovative approach and stock options. Revenues are based on the supply of targeted tumor delivery systems to specialized hospitals and surgical centers.

Rentabilitas dodolan resik RenovoRx, Inc. (RNXT): kanggo periode 04.07.2022 - 20.11.2026

Rincian metrik keuangan lan pasar RenovoRx Corporation (RNXT)

- nilai pasar lan prakiraan target analis:
Analisis komprehensif perusahaan:RenovoRx, Inc.
Produk dadi RenovoRx Corp

Sales margin measures the proportion of net profit to revenue, reflecting the efficiency of cost management relative to incoming cash flows. This indicator determines the business's margin of safety and its ability to survive a decline in demand. For RenovoRx, Inc. (RNXT), which is in the clinical trial stage without stable revenue, this metric highlights a critical dependence on external capital. The month-over-month sales margin trend visualizes the cash burn rate prior to product commercialization.